Pyruvate dehydrogenase complex deficiency: updating the clinical, metabolic and mutational landscapes in a cohort of Portuguese patients

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Pavlu Pereira, H (Author) Other; Silva, MJ (Author) Other; Florindo, C (Author) Other; Sequeira, S (Author) Other; Ferreira, AC (Author) Other; Duarte, S (Author) Other; Rodrigues, AL (Author) Other; Janeiro, P (Author) Other; Oliveira, A (Author) Other; Gomes, D (Author) Other; Bandeira, A (Author) Other; Martins, E (Author) Other; Gomes, R (Author) Other; Soares, S (Author) Other; de Almeida, IT (Author) Other; Vicente, JB (Author) Other; Rivera, I (Author) Other

Journal

Title: Orphanet Journal of Rare Diseases

Vol. 15

ISSN: 1750-1172

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 1 Citation

Other information

Authenticus ID: P-00S-YX5

DOI: 10.1186/s13023-020-01586-3

Abstract (EN): Background The pyruvate dehydrogenase complex (PDC) catalyzes the irreversible decarboxylation of pyruvate into acetyl-CoA. PDC deficiency can be caused by alterations in any of the genes encoding its several subunits. The resulting phenotype, though very heterogeneous, mainly affects the central nervous system. The aim of this study is to describe and discuss the clinical, biochemical and genotypic information from thirteen PDC deficient patients, thus seeking to establish possible genotype-phenotype correlations. Results The mutational spectrum showed that seven patients carry mutations in thePDHA1gene encoding the E1 alpha subunit, five patients carry mutations in thePDHXgene encoding the E3 binding protein, and the remaining patient carries mutations in theDLDgene encoding the E3 subunit. These data corroborate earlier reports describingPDHA1mutations as the predominant cause of PDC deficiency but also reveal a notable prevalence ofPDHXmutations among Portuguese patients, most of them carrying what seems to be a private mutation (p.R284X). The biochemical analyses revealed high lactate and pyruvate plasma levels whereas the lactate/pyruvate ratio was below 16; enzymatic activities, when compared to control values, indicated to be independent from the genotype and ranged from 8.5% to 30%, the latter being considered a cut-off value for primary PDC deficiency. Concerning the clinical features, all patients displayed psychomotor retardation/developmental delay, the severity of which seems to correlate with the type and localization of the mutation carried by the patient. The therapeutic options essentially include the administration of a ketogenic diet and supplementation with thiamine, although arginine aspartate intake revealed to be beneficial in some patients. Moreover, in silico analysis of the missense mutations present in this PDC deficient population allowed to envisage the molecular mechanism underlying these pathogenic variants. Conclusion The identification of the disease-causing mutations, together with the functional and structural characterization of the mutant protein variants, allow to obtain an insight on the severity of the clinical phenotype and the selection of the most appropriate therapy.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 14